Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
# MC2115
Chicago, IL 60637Phone+1 773-702-4400Fax+1 773-702-3163
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
- University of ChicagoResidency, Internal Medicine, 2004 - 2006
- University of North Carolina HospitalsResidency, Internal Medicine, 2003 - 2004
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003
Certifications & Licensure
- IL State Medical License 2004 - 2026
- NC State Medical License 2003 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Investigation of Genetic Determinants of Capecitabine Toxicity Start of enrollment: 2009 Nov 01
- Investigation of Cisplatin-Related Kidney Toxicity Start of enrollment: 2009 Sep 22
- Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1594 citationsPan-cancer analysis of whole genomesPeter J. Campbell, Gad Getz, Jan O. Korbel, Joshua M. Stuart, Jennifer L. Jennings
Nature. 2020-02-06 - 37 citationsGermline pharmacogenomics in oncology: Decoding the patient for targeting therapyPeter H. O'Donnell, Mark J. Ratain
Molecular Oncology. 2012-04-01 - 126 citationsEnfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden
The Lancet. Oncology. 2021-06-01
Press Mentions
- ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
- UTSW Finds Potential Key to Predict Immunotherapy ToxicityAugust 15th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: